IPSC IPSC
Company Profile ↓Company Overview
IPSC (IPSC) is a publicly traded company listed on with a market capitalization of $171.54M. The valuation, growth and price-trend signals below summarize what matters most to investors and traders evaluating the stock.
Why Investors Should Care
Revenue has grown at a 175.9% CAGR over the past five years.
Carries low leverage with a debt-to-equity ratio of 0.27.
Recent Developments
- Dec 2025 Revenue of $109.16M (+1556.8% YoY); net profit $-9.58M.
- Trailing 12 Months Year-on-year growth — revenue +1556.8%.
- 5-Year Trend Long-term compounding — revenue CAGR 175.9%.
Growth & Price Performance
Compounded Sales Growth
| 5 Years: | 175.88% |
| 1 Year: | 1,556.76% |
Stock Price Performance
| 1 Year: | +246.90% |
| 6 Months: | +6.52% |
| 3 Months: | -14.41% |
| 1 Month: | -15.15% |
Highlights auto-generated from reported financials and price data; not investment advice. Verify with official filings before acting.
- Price vs 50-DMABelow
- Price vs 200-DMAAbove
- RSI (14)38.73 · Neutral
Auto-generated from price history and fundamentals; not investment advice.
Price Chart
Technical Trend
Computed from daily close history using EMA cross, slope, and RSI signals.
Note: intraday data is not stored locally. “Hourly” uses the most recent 10 daily candles as a short-term proxy.
Fundamental Growth Charts
No fundamental data available for this stock.
Interactive charts for Revenue, Net Income, EBITDA, Free Cash Flow, EPS, ROE, ROCE, Gross/Net/Operating Margin and more — switch metric and period using the dropdowns above. CAGR is computed across the displayed window (quarterly CAGR is annualised). Visual growth charts make it easy to spot multi-year compounding trends at a glance — far faster than reading raw numbers in a table.
PROS
- Compounding revenue at 175.9% over 5 years.
- In a confirmed uptrend (50-DMA above 200-DMA).
CONS
- Trading 33.3% below its 52-week high.
* The pros and cons are auto-generated from financial metrics.
Valuation
Growth (CAGR)
Profitability & Returns
Balance Sheet & Liquidity
Ownership
Financial Snapshot
Financial Statements Quarterly Results · Profit & Loss · Balance Sheet · Cash Flows · Ratios
Quarterly Results
Figures in USD.
| Metric | Mar 2020 | Jun 2020 | Sep 2020 | Mar 2021 | Jun 2021 | Sep 2021 | Mar 2022 | Jun 2022 | Sep 2022 | Mar 2023 | Jun 2023 | Sep 2023 | Mar 2024 | Jun 2024 | Sep 2024 | Mar 2025 | Jun 2025 | Sep 2025 | Mar 2026 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | - | - | - | - | - | - | 1.06M | 1.40M | 2.22M | 1.72M | 99.00K | 148.00K | 855.00K | 771.00K | 791.00K | 109.16M | - | - | - |
| Operating Income | - | -15.52M | -13.13M | -18.06M | -23.02M | -25.83M | -37.44M | -31.35M | -31.74M | -32.08M | -35.08M | -35.63M | -31.31M | -34.76M | -34.79M | 74.18M | -34.66M | -36.12M | -23.68M |
| Net Income | -9.67M | -15.30M | -13.07M | -18.35M | -23.27M | -26.01M | -37.51M | -30.99M | -30.75M | -31.26M | -33.29M | -32.72M | -28.06M | -31.21M | -31.23M | 76.56M | -32.54M | -34.42M | -21.64M |
| Diluted EPS | - | - | -1.75 | -2.39 | -1.93 | -0.48 | -0.66 | -0.54 | -0.53 | -0.53 | -0.56 | -0.55 | -0.45 | -0.38 | -0.37 | 0.89 | -0.38 | -0.40 | -0.11 |
| R&D Expense | - | 8.48M | 10.81M | - | 18.93M | 19.55M | - | - | - | - | - | - | - | - | - | - | - | 12.00K | - |
Profit & Loss (Annual)
Figures in USD.
| Metric | Dec 2020 | Dec 2021 | Dec 2022 | Dec 2023 | Dec 2024 | Dec 2025 |
|---|---|---|---|---|---|---|
| Revenue | - | - | 5.20M | 2.23M | 6.59M | 109.16M |
| Operating Income | -53.90M | -94.88M | -133.83M | -146.55M | -138.14M | -17.27M |
| Net Income | -53.58M | -95.82M | -130.93M | -136.67M | -126.57M | -9.58M |
| Diluted EPS | -7.16 | -2.96 | -2.96 | -2.30 | -1.61 | -0.14 |
| R&D Expense | 39.68M | 75.65M | - | - | - | - |
Balance Sheet (Annual)
Figures in USD.
| Metric | Dec 2019 | Dec 2020 | Dec 2021 | Dec 2022 | Dec 2023 | Dec 2024 | Dec 2025 |
|---|---|---|---|---|---|---|---|
| Total Assets | - | 106.78M | - | 486.54M | 360.69M | 353.22M | 223.70M |
| Current Assets | - | - | - | 319.72M | 176.99M | 194.05M | 120.77M |
| Cash & Equivalents | - | 27.21M | - | 84.27M | 47.32M | 58.44M | 61.85M |
| Inventory | - | - | - | - | - | - | - |
| Receivables | - | - | - | 780.00K | 2.23M | 1.52M | 667.00K |
| Total Liabilities | - | 33.43M | - | 183.81M | 175.94M | 191.85M | 64.77M |
| Current Liabilities | - | 12.11M | - | 29.82M | 17.85M | 129.78M | 20.23M |
| Long Term Debt | - | 9.64M | 8.90M | 3.74M | - | - | - |
| Total Debt | - | - | - | 49.41M | 48.17M | 53.83M | 43.56M |
| Total Equity | -91.86M | -106.41M | - | 302.74M | 184.75M | 161.36M | 158.94M |
| Shares Outstanding | - | - | - | 58.47M | 60.34M | 85.84M | 87.52M |
Cash Flows (Annual)
Figures in USD.
| Metric | Dec 2020 | Dec 2021 | Dec 2022 | Dec 2023 | Dec 2024 | Dec 2025 |
|---|---|---|---|---|---|---|
| Operating Cash Flow | -41.27M | -89.00M | 14.05M | -88.35M | -110.14M | -103.88M |
| Investing Cash Flow | -22.76M | -298.34M | -13.13M | 61.13M | 47.48M | 107.50M |
| Financing Cash Flow | 47.69M | 417.77M | 27.16M | -9.72M | 74.56M | 173.00K |
| Capital Expenditure | -9.82M | -44.97M | -30.60M | -13.74M | -154.00K | -848.00K |
| Free Cash Flow | -51.09M | -133.97M | -16.55M | -102.08M | -110.29M | -104.72M |
Ratios (Annual)
Figures in %.
| Metric | Dec 2020 | Dec 2021 | Dec 2022 | Dec 2023 | Dec 2024 | Dec 2025 |
|---|---|---|---|---|---|---|
| Gross Margin % | - | - | - | - | - | - |
| Operating Margin % | - | - | -2,574.2% | -6,556.9% | -2,096.5% | -15.8% |
| Net Margin % | - | - | -2,518.4% | -6,115.1% | -1,920.9% | -8.8% |
| ROE % | 50.3% | - | -43.2% | -74.0% | -78.4% | -6.0% |
| ROCE % | -56.9% | - | -29.3% | -42.7% | -61.8% | -8.5% |
Shareholding Pattern
Analyst View
Analyst aggregate. Targets and ratings update periodically; not investment advice.
Latest News
Recent headlines for IPSC
Will Century Therapeutics (NASDAQ:IPSC) Spend Its Cash Wisely? - simplywall.st
<a href="https://news.google.com/rss/articles/CBMi5wFBVV95cUxOdXdvNkswbWRPVnFKR0FkLUtCMHVvVGtpUlJzb1Y4ci1ySTg5S0NuVlQ3VFpkdUgwVEppM3ZmQm9Vc1F3R1dPZHFSYjlpckNDYzctcFJGYndMLWR2OGFZOFRIUGc1U0VUQ1lpc0phY3ZkOEdiTW5JQm1Gd2t3TTRpczM4bmRmcXlacHlRdl…
Fast-paced Momentum Stock Century Therapeutics (IPSC) Is Still Trading at a Bargain - Yahoo Finance
<a href="https://news.google.com/rss/articles/CBMihgFBVV95cUxNTGh1Y1paWm1ycmFDX3dtazh2Tlo4cENibnBHd2dVRTBlekc4SXdNdVlNdWZJWDZHR2czdWxrTWwyZlVKZlFqbjJYQmwxRzlORUFodEs3MHB3VTRYTnNMM29TVnRSUFZIYUxyLXp4cmNtaEIwdUFrcWZ3U0JtZXNlVVZjNm1pdw?oc=5" t…
Century Therapeutics, Inc. Revenue Breakdown – NASDAQ:IPSC - TradingView
<a href="https://news.google.com/rss/articles/CBMid0FVX3lxTE9KRk1zdHB3VnMwSXdULTJjVEFScHZxLXBPM3JwZjRlVktBRUowOFR3LUd5T0FuaWt1OTlFd1FieGtPaWEzYkVOaWNaeGdlbTJFeXU4ekp2dDB6NW1jWXNWN1M3QlRjd1gxZi1zaHpEdHhWZDQ2bEFN?oc=5" target="_blank">Century…
EUDA Health MOU Targets Off-the-Shelf Cancer Cell Therapies - Stock Titan
<a href="https://news.google.com/rss/articles/CBMivAFBVV95cUxPbHJ3Ry0xN3Fua3JTOUZGVUNtVlJvTlFYUS1YbTJkVkVoeU1LVS02U3dFZTlldWtFQjQxMW43R1pHanlfRExVaFpzeUJnY3poTnBvZTFSLWVYNlo3X3MyLWJmdFN1a0h6aFlYZmlYQXhUVm5rbkppQjJyTkQwSVpBckxhbVJoV0x3MWk4Mm…
IPSC|Century Therapeutics Inc|Price:2.065|Chg%:+0.015 - TradingKey
<a href="https://news.google.com/rss/articles/CBMibkFVX3lxTE5KMlkzR0RTbXdaaVN3RmcyZ3RCU2xCU2tVT2lhTHJSMmlqMzYzS0Q3YmU1dE9BNUVBaGdkZHRJYTdNQjNKWG5uSUlXS190NENRTFdOdkdQWGtLQUt1MVFTMElpY2FvU0NfYlRFZHhn?oc=5" target="_blank">IPSC|Century Therap…
IPSC Earning Date, Earning Analysis and Earning Prediction - Intellectia AI
<a href="https://news.google.com/rss/articles/CBMiWEFVX3lxTFBzZXd3enVBclNIQ3A1ZGRhb19oejdpYV9DUmxEXzFidWNqOEl0ejg0REFWX3JLVkRDVzNOMWVGdC1sWFhPazF2RXZGM1RuQzY4NWUzd2tLYlQ?oc=5" target="_blank">IPSC Earning Date, Earning Analysis and Earning …
IPSC — Frequently Asked Questions
What is the current share price of IPSC?
As of 2026-08-05 17:25 PDT, IPSC trades at $1.96 on NASDAQ/NYSE. Its 52-week range is $0.46 to $2.94.
What is the market capitalisation of IPSC?
IPSC has a market capitalisation of $171.54M on NASDAQ/NYSE.
What is the P/E ratio of IPSC?
IPSC trades at a trailing price-to-earnings (P/E) ratio of -14.00. Its price-to-book (P/B) ratio is 1.08.
What is the return on equity (ROE) of IPSC?
IPSC has a return on equity (ROE) of -6.03%. Its return on capital employed (ROCE) is -8.49%.
Is IPSC a good stock to buy?
This page provides a data-driven analysis of IPSC, including valuation ratios, profitability, growth trends, auto-generated pros and cons, peer comparison and AI exposure. Review these fundamentals alongside your own research and risk tolerance. This is informational content, not investment advice.